Prognostic significance of FAT10 expression in malignant tumors: a systematic review and meta-analysis.
Future Oncol
; 20(21): 1505-1514, 2024.
Article
em En
| MEDLINE
| ID: mdl-38864667
ABSTRACT
Aim:
FAT10, a ubiquitin-like modifier protein, influences apoptosis, DNA damage response and tumor growth, with unclear effects on cancer prognosis.Methods:
We reviewed FAT10 expression's impact on malignancy prognosis through a systematic review and meta-analysis, including studies up to September 2023 from PubMed, EMBASE and Web of Science.Results:
From 18 studies involving 2513 patients, FAT10 overexpression significantly reduced overall and disease-free survival across various tumors, indicating correlations with advanced disease stage, poor differentiation, lymph node metastasis and larger tumor size.Conclusion:
FAT10's overexpression suggests a negative prognostic value in cancer, meriting further investigation.PROSPERO Registration Number CRD42023431287.
This study investigated a protein called FAT10, which is involved in how cells behave, including how cancer cells grow and survive. It analyzed previous research to see if high levels of FAT10 in patients with cancer can help predict how serious their cancer is and how it might progress. After reviewing 18 studies involving 2513 patients, we found that patients with more FAT10 in their cells often had a worse outlook, including a higher chance of the cancer returning and a shorter overall survival time. This pattern existed for different types of cancer. Our findings suggest that measuring FAT10 levels could be helpful for doctors to better understand a patient's cancer and choose the best treatment. However, more studies are needed to confirm our results.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
/
Future oncol
/
Future oncology
Ano de publicação:
2024
Tipo de documento:
Article